VivoSeq
Other

Hearing Loss

41

Pipeline Programs↗

15

Active Trials↗

27

Companies Involved↗

Hearing Loss is a moderately active landscape with 41 programs across 27 companies. The most active players are Biogen, Kiniksa Pharmaceuticals (UK), Ltd., Sound Pharmaceuticals, Incorporated. 13 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

27/100

Mech. Concentration

33/100

Completion Rate

76/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Biogen logo

Biogen

1 program

Phase 1K

Kiniksa Pharmaceuticals (UK), Ltd.

1 program

Phase 1S

Sound Pharmaceuticals, Incorporated

2 programs

Phase 2GSK logo

GSK

1 program

Phase 2A

Acousia Therapeutics GmbH

1 program

Phase 2S

Sensorion

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical4

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

TJ0113

Hangzhou PhecdaMed Co., Ltd.

Ginaton

Peking University People's Hospital

Dexamethasone or Methylprednisolone

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 15

Anakinra

Swedish Orphan Biovitrum

Rilonacept

Kiniksa Pharmaceuticals (UK), Ltd.

N-Acetylcysteine

Novartis

Fludrocortisone

Alnylam Pharmaceuticals

PF-04958242

Biogen

Phase 214

Sodium Thiosulfate

Hope Pharmaceuticals

Valganciclovir

Engelhard Arzneimittel GmbH & Co.KG

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Ebselen

Sound Pharmaceuticals, Incorporated

OTO-104

Otonomy, Inc.

Phase 35

Proton Pump Inhibitor

AVM Biotechnology Inc

Alpha Lipoic Acid

National Center for Complementary and Integrative Health (NCCIH)

Laboratory Biomarker Analysis

US Department of Veterans Affairs

AM-111

Auris Medical AG

Dexamethasone-Dihydrogenphosphate

University Hospital Tuebingen

Approved13

Statin

Bristol-Myers Squibb

Ciprofloxacin

Bayer

Mannitol

B. Braun Medical Inc.

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Zonisamide

Azurity Pharmaceuticals

Analysis

Modality Breakdown

98%

Small molecule

43 of 44 classified programs — the dominant modality here.

2%ALL OTHERSProtein / enzyme12%

Small molecule leads; the ring shows all 44 classified programs, each share of the total. Modality classified for 98% of 47 pipeline programs.

Analysis

Trial Status

42

clinical trials

Completed16 · 38%
Recruiting10 · 24%
Unknown status6 · 14%
Not yet recruiting5 · 12%
Terminated3 · 7%
Withdrawn2 · 5%

Clinical Trials

Trial Activity

42 trials

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
Recruiting·National Institute on Deafness and Other Communication Disorders (NIDCD)·Phase 2·NCT04915183·224 enrolled
ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving Cisplatin
Recruiting·AAcousia Therapeutics GmbH·Phase 2·NCT06521190·40 enrolled
Effects of Bisphosphonates on OI-Related Hearing Loss
Recruiting·HHospital for Special Surgery, New York·Phase 4·NCT04152551·100 enrolled
Effectiveness of Integrative Medical Treatment in Sudden Hearing Loss
Recruiting·—·N/A·NCT07235488·64 enrolled
Oral Statins and Protection From Hearing Loss
Recruiting·NNorthwestern University·Phase 4·NCT04826237·100 enrolled
A Phase 1/2, Open-label, Single Dose Study of SKY-GJB2 Given as a Single Unilateral Intracochlear Administration in Pediatric Subjects With GJB2-mediated Hearing Loss
Recruiting·SSkylark Bio Inc.·Preclinical·NCT07627971·10 enrolled
Evaluation of Clinical Outcomes of Ponto Procedures Performed in Settings Outside the Main Operating Room (i.e. Out-of-OR)
Recruiting·OOticon Medical·N/A·NCT06930781·270 enrolled
A WhatsApp-Delivered AI-Enabled Support Programme Versus Paper-Based Support for First-Time Hearing Aid Users in Low-Resource Communities: A Randomized Controlled Trial
Recruiting·UUniversity of Pretoria·Preclinical·NCT07690670·66 enrolled
A Phase 1/2, Open-Label, Multicenter Trial With a Single Ascending Dose Cohort With Unilateral Intracochlear Injection Followed by a Bilateral Injection Expansion Cohort to Evaluate the Safety, Tolerability, and Efficacy of DB-OTO in Children and Infants With Biallelic hOTOF Mutations
Recruiting·Regeneron logoRegeneron·Preclinical·NCT05788536·36 enrolled
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Adults Receiving a Cochlear Implant
Recruiting·SSound Pharmaceuticals, Incorporated·Phase 2·NCT06340633·40 enrolled
A Clinical Trial of the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing Loss
Not yet recruiting·—·N/A·NCT07012746·60 enrolled
Evaluation of Oral Corticosteroid Therapy in Idiopathic Sudden Unilateral Hearing Loss.
Not yet recruiting·—·Phase 3·NCT07067801·430 enrolled
Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss
Not yet recruiting·SSeoul National University Hospital·Phase 1/2·NCT06437054·26 enrolled
HEARS Maryland: Extending Capacity for Affordable, Accessible Hearing Care Through Older Adult Peer Mentorship
Not yet recruiting·JJohns Hopkins University·Preclinical·NCT07699146·300 enrolled
Randomized Study of Same-Day Activation Versus Day-14 Activa- Tion in Adult Cochlear Implant Recipients
Not yet recruiting·UUniversity of Aarhus·Preclinical·NCT07681830·100 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)